Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 418

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 418
---
 by $24,270, or 3.6%, from $672,336 for the six months ended December 31, 2023, to $696,606 for the six months ended December 31, 2024. The increase was entirely attributable to a price effect, as the number of samples processed remained substantially consistent between periods, indicating a neutral volume effect.

213 Revenues from the Rewell segment increased by $107,120, or 344.9%, from $31,056 for the six months ended December 31, 2023, to $138,176 for the six months ended December 31, 2024. This growth is explained as follows: • volume effect: 79% of the increase is due to a 61% growth in the number of kits sold, reflecting expanded commercialization efforts and improved sales strategies; and • price effect: 21% of the increase is due to a 20% rise in the average price per kit, which is quoted in U.S. dollars, driven by adjustments in pricing strategies and increased direct -to -consumersales. Overall, approximately 83% and 17% of total revenues were derived from the Heritas Diagnostics segment and the Rewell segment, respectively, in the six months ended December 31, 2024, compared to 95.6% and 4.4%, respectively, in the six months ended December 31, 2023. Cost of revenues Cost of revenues increased by $301,444, or 39.7%, from $759,520 for the six months ended December 31, 2023, to $1,060,964 for the six months ended December 31, 2024. The observed increase occurred despite test volumes remaining relatively stable for the six -monthperiods, with 3,424 tests processed for the six -monthperiod ending December 31, 2023, compared to 3,479 tests processed for the six -monthperiod ending December 31, 2024, reflecting only a marginal change in the number of units processed. A portion of the increase is also attributable to the higher share of revenues coming from Rewell, while Rewell sales expanded during the period, its impact on cost of revenues was not material, given its relatively limited scale compared to the Diagnostics segment. The increase was primarily driven by the following factors: • Increase in Salaries and Severance Costs Due to Restructuring:The Company implemented a salary increase for laboratory staff